| Saturday, June 1 |
| 8:00 am – 11:00 am |
Design and Development of the Molecular Analysis for Therapy Choice (NCI-MATCH) Designated Laboratory Network 
|
Poster: 8
Abstract: 3016 |
| 8:00 am – 11:00 am |
Development and Analytical Validation of a 523-gene Clinical Assay for Cell-free DNA
|
Poster: 31
Abstract: 3039 |
| 8:00 am – 11:00 am |
Safety and Tolerability of Veliparib, an Oral PARP Inhibitor, and M6620 (VX-970), an ATR Inhibitor, in combination with Cisplatin in Patients with Refractory Solid Tumors
|
Poster: 59
Abstract: 3067 |
| 8:00 am – 11:00 am |
Integrative Analyses of Signaling and DNA Damage Repair Pathways in Patient-derived Xenograft (PDX) Models from NCI’s Patient-Derived Models Repository (PDMR)
|
Poster: 103
Abstract: 3111 |
| 8:00 am – 11:00 am |
Measuring Phospho-MET by Multiplex Immunofluorescence to Aid in Selection of Patients with MET Activation in Tumors
|
Poster: 123
Abstract: 3131 |
| 8:00 am – 11:00 am |
Pharmacodynamics of PI3K, MEK, and AKT Inhibitors through Isoform-specific Measurements of MEK, ERK, AKT, and ribosomal protein S6 in Needle Biopsies
|
Poster 126:
Abstract 3134 |
| 8:00 am – 11:00 am |
Phase I Trial of 5-aza-4’-thio-deoxycytidine (Aza-TdC) in Patients with Advanced Solid Tumors
|
Poster: 139a
Abstract: TPS3148 |
| 8:00 am – 11:00 am |
Organ Disfunction (dys) and Clinical Outcomes in Patients (pts) Treated with Immune Checkpoint Inhibitors (ICIs)
|
Poster: 213
Abstract: 2569 |
| 8:00 am – 11:00 am |
TMB Standardization by Alignment to Reference Standards: Phase II of the Friends of Cancer Research TMB Harmonization Project
|
Poster: 268
Abstract: 2624 |
| 8:00 am – 11:00 am |
A Multiplex Immunofluorescence Assay to Assess Immune Checkpoint Inhibitor-targeted CD8 Activation and Tumor Colocalization in FFPE Tissues
|
Poster: 273
Abstract: 2629 |
| 8:00 am – 11:00 am |
SWOG 1609 (DART): A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
|
Poster: 295a
Abstract: TPS2658 |
| 8:00 am – 11:00 am |
Evaluation of the Multi-kinase Inhibitor Regorafenib in the Pediatric Preclinical Testing Consortium Osteosarcoma, Rhabdomyosarcoma, and Ewing Sarcoma In Vivo Models
|
Poster: 420
Abstract: 10038 |
| 1:15 pm – 4:15 pm |
A Randomized Double-blind Placebo-controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination with Adavosertib in Women with Recurrent, Platinum Resistant Epithelial Ovarian Cancer: A Trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia
|
Poster: 341
Abstract: 5518 |
| Sunday, June 2 |
| 8:00 am – 11:00 am |
A Phase Ib Trial of CB-839 (Telaglenastat) in Combination with Radiation Therapy and Temozolomide in Patients with IDH-mutated Diffuse Astrocytoma and Anaplastic Astrocytoma (NCT03528642)
|
Poster: 262a
Abstract: TP2075 |
| Monday, June 3 |
| 8:00 am – 11:00 am |
The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089/NCT03038672)
|
Poster: 322a
Abstract: TPS7570 |
| 1:15 pm – 4:15 pm |
Treatment Completion and Toxicity of Trastuzumab or Trastuzumab + Lapatinib in Older Patients (pts): BIG 2-06; NCCTG N063D (Alliance)
|
Poster: 245
Abstract 11553 |
| 1:15 pm – 4:15 pm |
A Randomized Phase II Study of Atezolizumab Plus Recombinant Human IL-7 (CYT107) or Atezolizumab Alone in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (mUC): A Cancer Immunotherapy Trials Network Trial (CITN-14)
|
Poster: 412a
Abstract: TPS4586 |
